Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SDHA | P31040 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3578705 | 0.97 | ALDH1A1 (0.37) | CALML3ALDH1A1MAOAMAOBCYP3A4 | |
| SCHEMBL1393639 | 0.88 | CALML3 (0.40) | CALML3ALDH1A1MAOAMAOBCYP3A4 | |
| SCHEMBL1394275 | 0.87 | MAOA (0.51) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL1394084 | 0.85 | ALOX5AP (0.42) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL1394945 | 0.82 | CALML3 (0.39) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL3578709 | 0.82 | MAOA (0.48) | CALML3MAOAMAOBLMNAPTGS1 | |
| SCHEMBL3085608 | 0.82 | CALML3 (0.40) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL1394027 | 0.79 | CALML3 (0.45) | CALML3MAOAMAOBCYP3A4CYP2C19 | |
| SCHEMBL3093094 | 0.77 | CTSS (0.39) | CALML3CYP3A4 | |
| SCHEMBL3096328 | 0.77 | MAOA (0.49) | CALML3MAOAMAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | RIB-X PHARMACEUTICALS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7148219-B2 | Biaryl heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234591-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885ALDH1A1 2099/4885MAOA 872/4885 |
| US-20150072970-A1 | BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PCNA, AADAC, MIF | CALML3 3842/4885ALDH1A1 2099/4885MAOA 872/4885 |
| US-20120010200-A1 | Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same | PCNA, AADAC, MIF | CALML3 3842/4885ALDH1A1 2099/4885MAOA 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.